Future novel therapeutic agents for Clostridium difficile infection

Expert Opinion on Investigational Drugs

Volumn 19, Issue 7, 2010, Pages 825-836

  Koo, Hoonmo L ^a,b   Garey, Kevin W ^a,b,c   Dupont, Herbert L ^a,b,d,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Antibiotic; Clostridium difficile; Treatment

Indexed keywords

METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; RAMOPLANIN; RIFALAZIL; RIFAMPICIN; RIFAXIMIN; TIACUMICIN B; TIGECYCLINE; TIZOXANIDE; VANCOMYCIN;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; BLOOD PRESSURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; INFECTION PREVENTION; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; NOSE CONGESTION; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; PROBIOTICS; TREATMENT OUTCOME;

EID: 77953375147     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.495386     Document Type: Review

References (106)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals 1996-2003. Emerg Infect Dis 2006; 12 (3): 409-415.
2. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S43-9
3. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171(5):466-472
4. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40(11):1586-1590
5. Jobe BA, Grasley A, Deveney KE, et al. Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg 1995;169(5):480-483
6. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007;13(9):1417-1419
7. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23):2442-2449
8. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34(3):346-353
9. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007;(3):CD004610
10. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):1-13
11. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16(8):459-477
12. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5(9):549-557
13. Pelaez T, Alcala L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46(6):1647-1650
14. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-307
15. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89(5):1038-1045
16. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42(6):758-764
17. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97(7):1769-1775
18. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44(6):846-848
19. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36(5):580-585
20. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362(3):197-205
21. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S32-42
22. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52(11):4163-4165
23. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48(12):4898-4902
24. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48(6):2280-2282
25. Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009;53(1):261-263
26. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35(6):1108-1111
27. Babakhani FK, Shangle S, Robert N, et al. Resistance development, cross-resistance, and synergy studies of OPT-80. Abstract E-2047. 44th ICAAC; 30 October-2 November 2004; Washington, DC, USA
28. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):223-228
29. Citron DM, Babakhani F, Goldstein EJ, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009;15(6):234-236
30. Golan Y, Mullane K, Miller M, et al. Low recurrence rate among patients (Pts) with C. difficile infection (CDI) treated with fidaxomicin (FDX). Abstract L1-1639. 49th ICAAC; 12-15 September 2009; San Francisco, USA
31. Gerding D, Sambol S, Nagaro K, et al. Restriction endonuclease analysis (REA) typing of Clostridium difficile in a Phase 3 Treatment Trial of fidaxomicin vs vancomycin: decreased cure rate for epidemic BI/NAP1/027 strain. Abstract L1-1642. 49th ICAAC; 12-15 September, 2009. San Francisco, USA
32. Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005;40(8):1173-1180
33. Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15(9):1409-1415
34. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184(1):103-106 (Pubitemid 32568508)
35. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43(4):421-427
36. Broekhuysen J, Stockis A, Lins RL, et al. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000;38(8):387-394
37. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48(4):e41-6
38. Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis 2006;43(4):428-431
39. Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59(4):705-710
40. Hartmann G, Honikel KO, Knusel F, Nuesch J. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta 1967;145(3):843-844
41. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14(2):51-56
42. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005;142(10):805-812
43. Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica 1990;5:74-77
44. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989;86(1):15-19
45. Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009;43(1):91-93
46. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008;52(8):2813-2817
47. Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48(4):425-429
48. Noren T, Alriksson I, Akerlund T, et al. In vitro susceptibility to 17 antimicrobials among clinical Clostridium difficile isolates collected 1993-2007 in Sweden. Clin Microbiol Infect 2009. [Epub ahead of print]
49. Jiang ZD, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 2010;63(4):355-358
50. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs 2006;7(8):740-749
51. Freeman J, Baines SD, Jabes D, Wilcox MH. Comparison of the efficacy of ramoplanin and vancomycin in both In vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005;56(4):717-725
52. Somner EA, Reynolds PE. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother 1990;34(3):413-419
53. Pelaez T, Alcala L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005;49(3):1157-1159
54. Wong MT, Kauffman CA, Standiford HC, et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001;33(9):1476-1482
55. Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother 2003;51(Suppl 3):iii31-5
56. TYGACIL® (tigecycline) [prescribing information]. Philadelphia PWPI, 2009
57. Hawser SP. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents 2010;35(1):97-98
58. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27(10):1169-1172
59. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006;50(10):3375-3380 (Pubitemid 44527513)
60. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48(12):1732-1735
61. Chen Y-X, Cobana B, Kivel N, et al. Escalating single-dose safety and pharmacokinetics of rifalazil in healthy volunteers. AAPS J 2004;6:M1103
62. Anton PM, O'Brien M, Kokkotou E, et al. Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother 2004;48(10):3975-3979
63. Dietze R, Teixeira L, Rocha LM, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001;45(7):1972-1976
64. Murphy CK, Mullin S, Osburne MS, et al. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50(3):827-834
65. Hoffman FA, Heimbach JT, Sanders ME, Hibberd PL. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Clin Infect Dis 2008;46(Suppl 2):S53-7
66. Elmer GW. Probiotics: "living drugs". Am J Health Syst Pharm 2001;58(12):1101-1109
67. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003;171(11):6164-6172
68. Wu X, Vallance BA, Boyer L, et al. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 2008;294(1):G295-306
69. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357(9251):189-193
70. Jayamanne VS, Adams MR. Determination of survival, identity and stress resistance of probiotic bifidobacteria in bio-yoghurts. Lett Appl Microbiol 2006;42(3):189-194
71. Masco L, Huys G, De Brandt E, et al. Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int J Food Microbiol 2005;102(2):221-230
72. Drisko J, Bischoff B, Giles C, et al. Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 2005;50(6):1113-1117
73. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40(11):1625-1634
74. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41(11):5340-5343
75. Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS 2006;17(4):280-282
76. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115(1):178-181
77. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999 May;28(5):1159-1160
78. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271(24):1913-1918
79. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008;(1):CD004611
80. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31(4):1012-1017
81. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35(6-7):365-367
82. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005;54(Pt 9):905-906
83. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7(1):59-62
84. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated Diarrhea and Clostridium difficile-associated Diarrhea prophylaxis in adult patients. Am J Gastroenterol. [Epub ahead of print]
85. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335(7610):80
86. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005;21(5):583-590
87. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998;36(2):171-174
88. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342(6):390-397
89. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 2008;26(27-28):3404-3409
90. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28(4):965-969
91. Kyne L. Clostridium difficile-beyond antibiotics. N Engl J Med 2010;362(3):264-265
92. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51(8):2716-2719
93. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44(8):2205-2206
94. Edlund C, Sabouri S, Nord CE. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1998;17(3):193-195
95. Betriu C, Rodriguez-Avial I, Gomez M, et al. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 2006;56(4):437-444
96. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44(9):2254-2258
97. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48(11):4430-4434
98. Finegold SM, Molitoris D, Vaisanen ML. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother 2009;53(1):281-286
99. Citron DM, Merriam CV, Tyrrell KL, et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003;47(7):2334-2338
100. Finegold SM, John SS, Vu AW, et al. In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Anaerobe 2004;10(4):205-211
101. Bishara J, Bloch Y, Garty M, et al. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006;54(2):141-144
102. Barbut F, Mastrantonio P, Delmee M, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007;13(11):1048-1057
103. Sundram F, Guyot A, Carboo I, et al. Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 2009;72(2):111-118
104. Betriu C, Rodriguez-Avial I, Sanchez BA, et al. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002;50(5):758-759
105. Golan Y, Mullane K, Miller M, et al. Low recurrence rate among patients (Pts) with C. difficile infection (CDI) treated with fidaxomicin (FDX). Abstract L1-1639. 49th ICAAC; 12-15 September 2009; San Francisco, CA, USA
106. Gerding D, Sambol S, Nagaro K, et al. Restriction endonuclease analysis (REA) typing of Clostridium difficile in a Phase 3 Treatment Trial of fidaxomicin vs vancomycin: decreased cure rate for epidemic BI/NAP1/027 Strain. Abstract L1-1642. 49th ICAAC; 12-15 September 2009; San Francisco, CA, USA